Literature DB >> 12924106

[Fibromyalgia syndrome].

Walter Siegmeth1.   

Abstract

Nowadays, fibromyalgia syndrome (FMS) should be diagnosed according to established criteria in order to differentiate it from other specified or unspecified pain conditions. Various underlying reasons for pain exist and possible correlations with FMS should be thoroughly discussed with the patient. Recent pathophysiological examinations suggest that fibromyalgia syndrome may constitute a disorder of the central nervous system, especially of the hypothalamus-hypophysis-axis, and/or of the autonomous nervous system and of pain regulating nerves. The most common co-morbidity comprises sleep disturbances. The patients' complaints usually prevail over a long period of time. There is a variety of trigger factors for the development of fibromyalgia syndrome, which leads to the suggestion that a number of fibromyalgia-syndrome subgroups exist. A genetic disposition is a topic of ongoing discussion. Treatment of fibromyalgia syndrome should be multidisciplinary. Drug therapy is often disappointing. Extensive patient information, therapeutic devotion and means of physical therapy seem to be more efficient, providing a multitude of therapeutic options. Both fibromyalgia syndrome and chronic fatigue syndrome have to be accepted as medical entities, treated efficiently and studied scientifically. By these means, patients suffering from fibromyalgia syndrome, will not be lost to non-established forms of therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12924106     DOI: 10.1046/j.1563-258x.2003.03037.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  34 in total

1.  Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia.

Authors:  M Martínez-Lavín; A G Hermosillo
Journal:  Semin Arthritis Rheum       Date:  2000-02       Impact factor: 5.532

Review 2.  Present state of medication therapy in fibromyalgia syndrome.

Authors:  J Lautenschläger
Journal:  Scand J Rheumatol Suppl       Date:  2000

3.  Cognitive behavioral treatment of fibromyalgia syndrome: preliminary findings.

Authors:  W R Nielson; C Walker; G A McCain
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

4.  Comorbidity of fibromyalgia with medical and psychiatric disorders.

Authors:  J I Hudson; D L Goldenberg; H G Pope; P E Keck; L Schlesinger
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

5.  Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami.

Authors:  R Kwiatek; L Barnden; R Tedman; R Jarrett; J Chew; C Rowe; K Pile
Journal:  Arthritis Rheum       Date:  2000-12

6.  Evidence of qualitatively altered nociception in patients with fibromyalgia.

Authors:  L Bendtsen; J Nørregaard; R Jensen; J Olesen
Journal:  Arthritis Rheum       Date:  1997-01

7.  A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia.

Authors:  D Goldenberg; M Mayskiy; C Mossey; R Ruthazer; C Schmid
Journal:  Arthritis Rheum       Date:  1996-11

8.  Fibromyalgia and quality of life: a comparative analysis.

Authors:  C S Burckhardt; S R Clark; R M Bennett
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

9.  Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome.

Authors:  I J Russell; J E Michalek; G A Vipraio; E M Fletcher; M A Javors; C A Bowden
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 10.  Advances in fibromyalgia: possible role for central neurochemicals.

Authors:  I J Russell
Journal:  Am J Med Sci       Date:  1998-06       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.